1. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980. 286:611–613.
2. Cousins SW, Guss RB, Howes EL Jr, Rosenbaum JT. Endotoxin-induced uveitis in the rat: observations on altered vascular permeability, clinical findings, and histology. Exp Eye Res. 1984. 39:665–676.
3. Bhattacherjee P, Williams RN, Eakins KE. An evaluation of ocular inflammation following the injection of bacterial endotoxin into the rat footpad. Invest Ophthalmol Vis Sci. 1983. 2:196–202.
4. Lightman S. Uveitis: management. Lancet. 1991. 338:1501–1504.
5. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin. 2006. 46:141–164.
6. Folk JE, Chung SI. Transglutaminases. Methods Enzymol. 1985. 113:358–375.
7. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002. 27:534–539.
8. Kim SY, Jeitner TM, Steinert PM. Transglutaminases in disease. Neurochem Int. 2002. 40:85–103.
9. Bruce SE, Bjarnason I, Peters TJ. Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin Sci. 1985. 68:573–579.
10. D'Argenio G, Biancone L, Cosenza V, et al. Transglutaminases in Crohn's disease. Gut. 1995. 37:690–695.
11. Choi YC, Park GT, Kim TS, et al. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2. J Biol Chem. 2000. 275:8703–8710.
12. Lee J, Kim YS, Choi DH, et al. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem. 2004. 279:53725–53735.
13. Suh GY, Ham HS, Lee SH, et al. A peptide with anti-transglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice. Exp Lung Res. 2006. 32:43–53.
14. Sohn J, Kim TI, Yoon YH, et al. Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest. 2003. 111:121–128.
15. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002. 8:143–149.
16. Broekhuyse RM, Kuhlmann ED, Winkens HJ, Van Vugt AH. Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis. I. Induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigment epithelium. Exp Eye Res. 1991. 52:465–474.
17. Kim SY. Transglutaminase 2 in inflammation. Front Biosci. 2006. 11:3026–3035.
18. Bowness JM, Tarr AH. Increase in transglutaminase and its extracellular products in response to an inflammatory stimulus by lipopolysaccharide. Mol Cell Biochem. 1997. 169:157–163.
19. Park KC, Chung KC, Kim YS, et al. Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia. Biochem Biophys Res Commun. 2004. 323:1055–1062.
20. Smith RS. Ultrastructural studies of the blood-aquous barrier. I. Transport of an electron-dense tracer in the iris and ciliary body of the mouse. Am J Ophthalmol. 1971. 71:1066–1077.
21. Shapiro AL, Scharff MD, Maizel JV, Uhr JW. Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature. 1966. 211:243–245.